Strides Pharma Science

Strides Pharma reports Q3 net loss of Rs 82 cr, revenue rises to Rs 865 cr

Strides Pharma Science on Tuesday reported a consolidated net loss of Rs 82 crore for the third quarter ended December 31, 2022. The drug firm had reported a net loss of Rs 127 crore in the October-December quarter of previous fiscal. Revenue from operations rose to Rs 865 crore for the quarter under review as against Rs 794 crore in the year-ago period, the company said in a regulatory filing. On a standalone basis, the company reported a net profit of Rs 12 crore as against a net loss of Rs 18 crore in the year-ago period, it added. The Bengaluru-based firm said the profit during the quarter was impacted by loss from JV and associates on account of inventory write off related to Covid portfolio. "We continue to focus on a profitable outcome for the business and have, by design, let go of several low margin businesses," Strides Pharma Science Founder, Managing Director and Executive Chairperson Arun Kumar said.

Strides Pharma gets USFDA nod for naproxen sodium softgel capsules

Strides Pharma Science Ltd on Thursday said its wholly-owned arm, Strides Pharma Global Pte Ltd, has received approval from the US health regulator for generic naproxen sodium softgel capsules, used to treat pain or inflammation. The approval by the US Food & Drug Administration (USFDA) is for naproxen sodium softgel capsules of 220 mg strength (over the counter), the company said in a regulatory filing. It is bioequivalent and therapeutically equivalent to the reference-listed drug, naproxen sodium capsules, 220 mg of Bionpharma Inc, it added. The product will be manufactured at the company's Bengaluru facility. Naproxen sodium softgel capsules is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps, the company said. Strides said it is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels, .

Stride Pharma Science Q1 net loss narrows to Rs 163 cr, revenue grows 36.6%

Strides Pharma Science Ltd on Friday reported a narrowing of consolidated net loss at Rs 163.4 crore in the quarter ended June 2022, aided by higher revenue

Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%

The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.

Strides Pharma hits 52-week low, slumps 9% on weak Q2 results

The management said a muted sales performance accompanied with a drop in gross margins and relatively higher operating costs has led to a negative operating leverage in H1

Strides Pharma posts Rs 43 cr Q4 profit vs Rs 207 cr loss a year ago

Company to launch generic products to aid Covid-19 treatment in India, first being Liposomal Amphotericin B to treat black fungus

Stelis CEO steps down after Indian firm signs deal for Russia vaccine

Roger Lias, who accepted the CEO job at unlisted Stelis in late 2019 when the pandemic was in its early stages, left on March 31

Strides Pharma Science arm gets USFDA nod for HIV treatment medicine

Strides Pharma Science said its step-down wholly-owned subsidiary, has received approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV

Strides dips 6% from high on profit booking as Aditya Puri joins as advisor

In the past six months, the stock has zoomed 130 per cent, as compared to 33 per cent rally in the S&P BSE Sensex

Strides Pharma Science gets USFDA nod for generic Prednisone tablets

Strides Pharma Science Ltd on Monday said it has received approval from the US health regulator for its generic version of Prednisone tablets, prescribed for a variety of conditions, including allergies, respiratory illness and arthritis. The approval for Prednisone tablets by the US Food & Drug Administration (USFDA) granted to the company's step-down wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore, is for multiple strengths of 2.5 mg and 5 mg, Strides Pharma Science said in a regulatory filing. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Deltasone tablets, 2.5 mg and 5 mg, of Pharmacia and Upjohn Co, it added. Citing IQVIA MAT September 2020 data, the company said the US market for Prednisone Tablets USP, 2.5 mg and 5 mg is approximately USD 30 million. "The product will be manufactured at the company's flagship facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market," it ...

Here are the top stock picks by Nilesh Jain of Anand Rathi Shares

The stock has formed a bearish Harami candlestick pattern on the daily chart which is considered as a bearish reversal pattern.

Strides Pharma shares zoom 8% on US FDA approval for Ursodiol tablets

Ursodiol is used for treatment of patients with primary biliary cirrhosis (PBC)

Strides Pharma Science Q1 net profit jumps over 4-fold to Rs 102 cr

Drug firm Strides Pharma Science on Wednesday reported over four-fold rise in its consolidated net profit at Rs 101.84 crore for the quarter ended June 30, 2020, mainly on account of a one-time gain. The company had posted a net profit of Rs 25.36 crore in the corresponding period of the previous fiscal, Strides Pharma Science said in a filing to the BSE. Total income of the company stood at Rs 794.10 crore in the quarter under consideration. It was at Rs 696.05 crore in the same period a year ago. The company had a gain of Rs 44.91 crore, shown as an exceptional item, in the quarter ended June this year. "We have reported strong performance across all our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment due to COVID-19," Strides Pharma Science MD & CEO R Ananthanarayanan said. "While our manufacturing and supply chain continue to remain steady without any significant disruptions, we remain cautiously optimistic on the outlook of our ..

Sun Pharma to test pancreatitis drug in Covid-19 patients in India

Sun Pharma it has initiated manufacturing of the active pharmaceutical ingredient and the finished product of the drug using technology from its unit, Pola Pharma Japan.

Strides posts pre-tax loss of Rs 217 cr in Q4 as ranitidine ban in US bites

Ranitidine was a $9 million business for Strides in the first half of FY20

Strides Pharma commences export of Favipiravir tablets; stock surges 15%

The drug has demonstrated positive outcomes, including a reduction in the duration of Covid-19 and improved lung conditions for the patients

Strides Pharma Science gets USFDA nod for generic anti-bacterial capsules

The product is a generic version of Achromycin V Capsules, 250 mg and 500 mg, of Avet Pharmaceuticals (previously Heritage Pharmaceuticals)

Strides Pharma Science inks deal with Pharmaceutics to buy 18 ANDAs for US

With access to these products, Strides will significantly expand its niche offerings on its front-end, which has grown multi-fold to attain a quarterly revenue size of $66 million

Strides Pharma posts threefold rise in profit-before-tax at Rs 103.6 crore

The Bengaluru-headquartered company posted a 358 per cent rise in net profit at 101 crore as compared to the corresponding quarter of the previous financial year

Strides Pharma Science may resume Ranitidine drug sale in US market

Strides' Ranitidine tablets 300 mg is within the acceptable limits for N-nitrosodimethylamine (NDMA) of 96 nanograms per day or 0.32 ppm